Clopidogrel in acute coronary syndrome: to genotype or not?
Storey
Robert F
RF
Cardiovascular Research Unit, University of Sheffield School of Medicine, Sheffield S10 2RX, UK. R.F.Storey@sheffi eld.ac.uk
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D000244:Adenosine Diphosphate / Q000378:metabolism / Q000502:physiology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000187:drug effects / Q000378:metabolism; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005838:Genotype; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine